Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Operations (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Cash from Operations for 9 consecutive years, with 14417000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 7.62% year-over-year to 14417000.0, compared with a TTM value of 41800000.0 through Dec 2025, up 7.41%, and an annual FY2025 reading of 41800000.0, up 7.41% over the prior year.
  • Cash from Operations was 14417000.0 for Q4 2025 at Puma Biotechnology, up from 9689000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 17259000.0 in Q3 2022 and bottomed at 26895000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 5627500.0, with a median of 10072000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations crashed 18648.65% in 2022, then surged 1272.35% in 2025.
  • Year by year, Cash from Operations stood at 5435000.0 in 2021, then surged by 241.36% to 7683000.0 in 2022, then skyrocketed by 36.08% to 10455000.0 in 2023, then soared by 49.28% to 15607000.0 in 2024, then fell by 7.62% to 14417000.0 in 2025.
  • Business Quant data shows Cash from Operations for PBYI at 14417000.0 in Q4 2025, 9689000.0 in Q3 2025, and 14094000.0 in Q2 2025.